On January 7, 2014, Zynex, Inc. received letters from each of Mats Wahlstrom, Mary Beth Vitale, Kevin Smith and Taylor Simonton, each members of the Company's Board of Directors, pursuant to which each director resigned from the Company's Board effective January 10, 2014. At the time of their respective resignations: Mr. Wahsltrom served as the Company's Lead Director and a member of the Board's Compensation Committee; Ms. Vitale served as the Chairperson of the Board's Compensation Committee and as a member of the Board's Audit Committee; Mr. Smith served as a member of the Board's Compensation Committee and Audit Committee; and Mr. Simonton served as the Chairperson of the Board's Audit Committee.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
